Literature DB >> 2740721

Particle deposition efficiency of therapeutic aerosols in the human maxillary sinus.

N Hyo1, H Takano, Y Hyo.   

Abstract

The deposition efficiency of therapeutic aerosol particles in the human maxillary sinus is evaluated both in the human body and in a model cast of the upper airway. In the experiments, three sample materials, such as mono-dispersed polystyrene latex particles, aqueous glucose solution and pure water, in the range of particle diameter of from 0.5 to 15.8 microns, are employed in the model cast. The radioactive labelled aerosol particle is also used in the human body. From the results of the experiment, it is confirmed that even though the maxillary sinus is a closed hollow organ, aerosol flow is able to be induced only when the pressure gradient is applied between the nasal cavity and the maxillary sinus. In this case, the particle deposition is is explained in relationship to the inertia impaction of the aerosol particles on the inside wall of the maxillary sinus. The total deposition efficiencies and the deposited particle sizes in the sinus area for both experiments, with the model and in the human body, are almost the same at 3%, and 3-10 microns in diameter, respectively. A physical model for this particle deposition suggests that these experimental values change not only with the size distributions of therapeutic particles and the pressure gradient, but also with the diameter of the sinus ostium. Moreover, since the therapeutic particle might not enter the maxillary sinus when the diameter of the sinus ostium canal is less than 1 mm, some pretreatment to open the sinus ostium canal would be necessary before applying such aerosol therapy in practice.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2740721

Source DB:  PubMed          Journal:  Rhinology        ISSN: 0300-0729            Impact factor:   3.681


  13 in total

1.  A new Strategy to Improve Drug Delivery to the Maxillary Sinuses: The Frequency Sweep Acoustic Airflow.

Authors:  Amira El Merhie; Laurent Navarro; Xavier Delavenne; Lara Leclerc; Jérémie Pourchez
Journal:  Pharm Res       Date:  2015-12-30       Impact factor: 4.200

2.  Ventilation imaging of the paranasal sinuses using xenon-enhanced dynamic single-energy CT and dual-energy CT: a feasibility study in a nasal cast.

Authors:  Sven F Thieme; Winfried Möller; Sven Becker; Uwe Schuschnig; Oliver Eickelberg; Andreas D Helck; Maximilian F Reiser; Thorsten R C Johnson
Journal:  Eur Radiol       Date:  2012-05-18       Impact factor: 5.315

3.  Topical Drug Delivery for Chronic Rhinosinusitis.

Authors:  Jonathan Liang; Andrew P Lane
Journal:  Curr Otorhinolaryngol Rep       Date:  2012-12-27

4.  Impact of airborne particle size, acoustic airflow and breathing pattern on delivery of nebulized antibiotic into the maxillary sinuses using a realistic human nasal replica.

Authors:  Lara Leclerc; Jérémie Pourchez; Gérald Aubert; Sandrine Leguellec; Laurent Vecellio; Michèle Cottier; Marc Durand
Journal:  Pharm Res       Date:  2014-03-04       Impact factor: 4.200

5.  Prevention of sinonasal inflammation by a synthetic glycosaminoglycan.

Authors:  Abigail Pulsipher; Xuan Qin; Andrew J Thomas; Glenn D Prestwich; Siam Oottamasathien; Jeremiah A Alt
Journal:  Int Forum Allergy Rhinol       Date:  2016-11-11       Impact factor: 3.858

Review 6.  Refractory chronic rhinosinusitis: pathophysiology and management of chronic rhinosinusitis persisting after endoscopic sinus surgery.

Authors:  Martin Desrosiers
Journal:  Curr Allergy Asthma Rep       Date:  2004-05       Impact factor: 4.919

7.  A computational study of functional endoscopic sinus surgery and maxillary sinus drug delivery.

Authors:  M R Wofford; J S Kimbell; D O Frank-Ito; V Dhandha; K A McKinney; G M Fleischman; C S Ebert; A M Zanation; B A Senior
Journal:  Rhinology       Date:  2015-03       Impact factor: 3.681

8.  Topical drug delivery in chronic rhinosinusitis patients before and after sinus surgery using pulsating aerosols.

Authors:  Winfried Möller; Uwe Schuschnig; Gülnaz Celik; Wolfgang Münzing; Peter Bartenstein; Karl Häussinger; Wolfgang G Kreyling; Martin Knoch; Martin Canis; Sven Becker
Journal:  PLoS One       Date:  2013-09-11       Impact factor: 3.240

9.  Update on the management of chronic rhinosinusitis.

Authors:  Rachel B Cain; Devyani Lal
Journal:  Infect Drug Resist       Date:  2013-01-23       Impact factor: 4.003

Review 10.  Novel drug-delivery systems for patients with chronic rhinosinusitis.

Authors:  Silviu Albu
Journal:  Drug Des Devel Ther       Date:  2012-05-31       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.